These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

215 related articles for article (PubMed ID: 37730274)

  • 21. AXL targeting restores PD-1 blockade sensitivity of
    Li H; Liu Z; Liu L; Zhang H; Han C; Girard L; Park H; Zhang A; Dong C; Ye J; Rayford A; Peyton M; Li X; Avila K; Cao X; Hu S; Alam MM; Akbay EA; Solis LM; Behrens C; Hernandez-Ruiz S; Lu W; Wistuba I; Heymach JV; Chisamore M; Micklem D; Gabra H; Gausdal G; Lorens JB; Li B; Fu YX; Minna JD; Brekken RA
    Cell Rep Med; 2022 Mar; 3(3):100554. PubMed ID: 35492873
    [TBL] [Abstract][Full Text] [Related]  

  • 22. SRC family kinase (SFK) inhibitor dasatinib improves the antitumor activity of anti-PD-1 in NSCLC models by inhibiting Treg cell conversion and proliferation.
    Redin E; Garmendia I; Lozano T; Serrano D; Senent Y; Redrado M; Villalba M; De Andrea CE; Exposito F; Ajona D; Ortiz-Espinosa S; Remirez A; Bertolo C; Sainz C; Garcia-Pedrero J; Pio R; Lasarte J; Agorreta J; Montuenga LM; Calvo A
    J Immunother Cancer; 2021 Mar; 9(3):. PubMed ID: 33658304
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Combination of oral STING agonist MSA-2 and anti-TGF-β/PD-L1 bispecific antibody YM101: a novel immune cocktail therapy for non-inflamed tumors.
    Yi M; Niu M; Wu Y; Ge H; Jiao D; Zhu S; Zhang J; Yan Y; Zhou P; Chu Q; Wu K
    J Hematol Oncol; 2022 Oct; 15(1):142. PubMed ID: 36209176
    [TBL] [Abstract][Full Text] [Related]  

  • 24. PD-1 Immune Checkpoint Blockade Promotes Therapeutic Cancer Vaccine to Eradicate Lung Cancer.
    Kadam P; Sharma S
    Vaccines (Basel); 2020 Jun; 8(2):. PubMed ID: 32570793
    [No Abstract]   [Full Text] [Related]  

  • 25. High SHP2 expression determines the efficacy of PD-1/PD-L1 inhibitors in advanced KRAS mutant non-small cell lung cancer.
    Feng HB; Chen Y; Xie Z; Jiang J; Zhong YM; Guo WB; Yan WQ; Lv ZY; Lu DX; Liang HL; Xu FP; Yang JJ; Yang XN; Zhou Q; Zhang DK; Zhang Z; Chuai SK; Zhang HH; Wu YL; Zhang XC
    Thorac Cancer; 2021 Oct; 12(19):2564-2573. PubMed ID: 34490728
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Dendritic Cell Vaccination in Non-Small Cell Lung Cancer: Remodeling the Tumor Immune Microenvironment.
    Abascal J; Oh MS; Liclican EL; Dubinett SM; Salehi-Rad R; Liu B
    Cells; 2023 Oct; 12(19):. PubMed ID: 37830618
    [TBL] [Abstract][Full Text] [Related]  

  • 27. BET Bromodomain Inhibition Cooperates with PD-1 Blockade to Facilitate Antitumor Response in
    Adeegbe DO; Liu S; Hattersley MM; Bowden M; Zhou CW; Li S; Vlahos R; Grondine M; Dolgalev I; Ivanova EV; Quinn MM; Gao P; Hammerman PS; Bradner JE; Diehl JA; Rustgi AK; Bass AJ; Tsirigos A; Freeman GJ; Chen H; Wong KK
    Cancer Immunol Res; 2018 Oct; 6(10):1234-1245. PubMed ID: 30087114
    [No Abstract]   [Full Text] [Related]  

  • 28. The impact of oncogenic driver mutations on neoadjuvant immunotherapy outcomes in patients with resectable non-small cell lung cancer.
    Shen Z; Teng M; Han L; Bian D; Zhang J; Zhu X; Qing Y; Hu S; Chen Y; Yao W; Yu H; Zhang L; Zhang P
    Cancer Immunol Immunother; 2023 Dec; 72(12):4235-4247. PubMed ID: 37932425
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Immune Checkpoint Blockade Enhances Immune Activity of Therapeutic Lung Cancer Vaccine.
    Kadam P; Singh RP; Davoodi M; Lee JM; John MS; Sharma S
    Vaccines (Basel); 2020 Nov; 8(4):. PubMed ID: 33167311
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Single-cell transcriptome analysis reveals TOX as a promoting factor for T cell exhaustion and a predictor for anti-PD-1 responses in human cancer.
    Kim K; Park S; Park SY; Kim G; Park SM; Cho JW; Kim DH; Park YM; Koh YW; Kim HR; Ha SJ; Lee I
    Genome Med; 2020 Feb; 12(1):22. PubMed ID: 32111241
    [TBL] [Abstract][Full Text] [Related]  

  • 31. CCL21 Programs Immune Activity in Tumor Microenvironment.
    Sharma S; Kadam P; Dubinett S
    Adv Exp Med Biol; 2020; 1231():67-78. PubMed ID: 32060847
    [TBL] [Abstract][Full Text] [Related]  

  • 32. In situ delivery of iPSC-derived dendritic cells with local radiotherapy generates systemic antitumor immunity and potentiates PD-L1 blockade in preclinical poorly immunogenic tumor models.
    Oba T; Makino K; Kajihara R; Yokoi T; Araki R; Abe M; Minderman H; Chang AE; Odunsi K; Ito F
    J Immunother Cancer; 2021 May; 9(5):. PubMed ID: 34049930
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Single-cell RNA sequencing reveals the effects of anti-PD-L1 therapy on 3LL lung cancer model and its tumor microenvironment.
    Zhang H; Huang H; Wu S; He X; Chen J; Zheng X; Chen L; Wang Z
    Med Oncol; 2023 Aug; 40(10):285. PubMed ID: 37653265
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Novel CCL21-vault nanocapsule intratumoral delivery inhibits lung cancer growth.
    Kar UK; Srivastava MK; Andersson A; Baratelli F; Huang M; Kickhoefer VA; Dubinett SM; Rome LH; Sharma S
    PLoS One; 2011 May; 6(5):e18758. PubMed ID: 21559281
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Co-mutations of TP53 and KRAS serve as potential biomarkers for immune checkpoint blockade in squamous-cell non-small cell lung cancer: a case report.
    Fang C; Zhang C; Zhao WQ; Hu WW; Wu J; Ji M
    BMC Med Genomics; 2019 Oct; 12(1):136. PubMed ID: 31619231
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Targeting immunosuppressive Ly6C+ classical monocytes reverses anti-PD-1/CTLA-4 immunotherapy resistance.
    Rodriguez BL; Chen L; Li Y; Miao S; Peng DH; Fradette JJ; Diao L; Konen JM; Alvarez FRR; Solis LM; Yi X; Padhye A; Gibson LA; Ochieng JK; Zhou X; Wang J; Gibbons DL
    Front Immunol; 2023; 14():1161869. PubMed ID: 37449205
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Pre-clinical characterization of GMP grade CCL21-gene modified dendritic cells for application in a phase I trial in non-small cell lung cancer.
    Baratelli F; Takedatsu H; Hazra S; Peebles K; Luo J; Kurimoto PS; Zeng G; Batra RK; Sharma S; Dubinett SM; Lee JM
    J Transl Med; 2008 Jul; 6():38. PubMed ID: 18644162
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Clonal expansion of resident memory T cells in peripheral blood of patients with non-small cell lung cancer during immune checkpoint inhibitor treatment.
    Kim H; Park S; Han KY; Lee N; Kim H; Jung HA; Sun JM; Ahn JS; Ahn MJ; Lee SH; Park WY
    J Immunother Cancer; 2023 Feb; 11(2):. PubMed ID: 36787939
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Chemokine C-C motif ligand 21 synergized with programmed death-ligand 1 blockade restrains tumor growth.
    Chen Q; Yin H; Pu N; Zhang J; Zhao G; Lou W; Wu W
    Cancer Sci; 2021 Nov; 112(11):4457-4469. PubMed ID: 34402138
    [TBL] [Abstract][Full Text] [Related]  

  • 40. A single institution study evaluating outcomes of PD-L1 high KRAS-mutant advanced non-small cell lung cancer (NSCLC) patients treated with first line immune checkpoint inhibitors.
    Kartolo A; Feilotter H; Hopman W; Fung AS; Robinson A
    Cancer Treat Res Commun; 2021; 27():100330. PubMed ID: 33581492
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 11.